Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer

Zhou, Qian; Xue, Lei; Xu, Aiqun; Li, Ziqi; He, Qinglian; Huang, Xiujuan; Xu, Guangxian; Tian, Faqing; Ding, Yuanlin; Zhu, Wei

doi:10.3389/fimmu.2022.724139

Cited by 14 publications

(12 citation statements)

References 168 publications

(137 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functionally, CCL3 promotes cancer growth by stimulating proliferation, migration, and invasion, acting via the TRAF6/NF-κB pathway [27]. Moreover, it recruits cancer-associated fibroblasts (CAFs) and is highly expressed in tumor-associated macrophages (TAMs) [33]. Furthermore, CCL3 has been reported to induce angiogenesis [34] and facilitate osteolytic bone metastases of several cancers [35].…”

Section: Discussionmentioning

confidence: 99%

“…CCL4 is also upregulated in CRC [25,30] and its systematic concentrations are elevated [31,32]. The chemokine acts similarly to CCL3 with respect to being a promoter of cancer cell proliferation and survival [33] and a facilitator of metastasis [37,42]. In turn, the anti-tumor effects of CCL4 are associated with recruitment of CD103 + DCs [33], responsible for priming and activating CD8 + T cells recruited into TME [43].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Macrophage Inflammatory Proteins (MIPs) Contribute to Malignant Potential of Colorectal Polyps and Modulate Likelihood of Cancerization Associated with Standard Risk Factors

Wierzbicki,

Bednarz-Misa,

Lewandowski

et al. 2024

IJMS

View full text Add to dashboard Cite

Better understanding of molecular changes leading to neoplastic transformation is prerequisite to optimize risk assessment and chemopreventive and surveillance strategies. Data on macrophage inflammatory proteins (MIPs) in colorectal carcinogenesis are scanty and their clinical relevance remains unknown. Therefore, transcript and protein expression of CCL3, CCL4, CXCL2, and CCL19 were determined in 173 and 62 patients, respectively, using RT-qPCR and immunohistochemistry with reference to polyps’ characteristics. The likelihood of malignancy was modeled using probit regression. With the increasing malignancy potential of hyperplastic–tubular–tubulo-villous–villous polyps, the expression of CCL3, CCL4, and CCL19 in lesions decreased. CCL19 expression decreased also in normal mucosa while that of CXCL2 increased. Likewise, lesion CCL3 and lesion and normal mucosa CCL19 decreased and normal CXCL2 increased along the hyperplasia–low–high dysplasia grade. The bigger the lesion, the lower CCL3 and higher CXCL2 in normal mucosa. Singular polyps had higher CCL3, CCL4, and CCL19 levels in normal mucosa. CCL3, CCL4 and CXCL2 modulated the likelihood of malignancy associated with traditional risk factors. There was no correlation between the protein and mRNA expression of CCL3 and CCL19. In summary, the polyp-adjacent mucosa contributes to gaining potential for malignancy by polyps. MIPs may help in specifying cancerization probability estimated based on standard risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Macrophage Inflammatory Proteins (MIPs) Contribute to Malignant Potential of Colorectal Polyps and Modulate Likelihood of Cancerization Associated with Standard Risk Factors

Wierzbicki,

Bednarz-Misa,

Lewandowski

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…However, treatment of CRC often fails due to acquired chemotherapy resistance, which is one of the main reasons for an individually poor prognosis in CRC patients. Because of this, intensive work has been carried out to identify mechanisms of CRC chemoresistance, including first analyses of the role of miRs in the chemoresistance of CRC cells and on the potential use of these RNAs for CRC treatment [ 76 , 77 , 78 ]. Interestingly, various studies have already shown that the miR examined in our study can re-sensitize tumor cells to certain chemotherapeutic agents, offering one opportunity for future therapeutic strategies based on our present data in CRC.…”

Section: Discussionmentioning

confidence: 99%

JAK1 Is a Novel Target of Tumor- and Invasion-Suppressive microRNA 494-5p in Colorectal Cancer

Patil,

Abdelrahim,

Leupold

et al. 2023

Cancers

View full text Add to dashboard Cite

MiR-494-5p expression has been suggested to be associated with colorectal cancer (CRC) and its metastases in our previous studies. However, functional investigations on the molecule-mediating actions of this miR in CRC are lacking. In silico analysis in the present study revealed a putative binding sequence within the 3′UTR of JAK1. Overexpression of miR-494-5p in cultured CRC significantly reduced the luciferase activity of a reporter plasmid containing the wild-type JAK1-3′UTR, which was abolished by seed sequence mutation. Furthermore, the overexpression of miR-494-5p in CRC cell lines led to a significant reduction in JAK1 expression, proliferation, in vitro migration, and invasion. These effects were abolished by co-transfection with a specific double-stranded RNA that inhibits endogenous miR-494-5p. Moreover, IL-4-induced migration, invasion, and phosphorylation of JAK1, STAT6, and AKT proteins were reduced after an overexpression of this miR, suggesting that this miR affects one of the most essential pathways in CRC. A Kaplan–Meier plotter analysis revealed that patients with high JAK1 expression show reduced survival. Together, these data suggest that miR-494-5p physically inhibits the expression of JAK1 at the translational level as well as in migration and invasion, supporting the hypothesis of miR-494-5p as an early tumor suppressor and inhibitor of early steps of metastasis in CRC.

show abstract

“…According to previous studies, chemokines can serve as biomarkers and targets for various tumors, including hepatocellular carcinoma [ 10 ], endometrial cancer [ 11 ], and colorectal cancer [ 12 ]. Recent studies highlighted the role of chemokines in the pathological progression of MM (Fig.…”

Section: Main Textmentioning

confidence: 99%

Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)

Du,

Lin,

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Background The incidence of multiple myeloma (MM), a type of blood cancer affecting monoclonal plasma cells, is rising. Although new drugs and therapies have improved patient outcomes, MM remains incurable. Recent studies have highlighted the crucial role of the chemokine network in MM’s pathological mechanism. Gaining a better understanding of this network and creating an overview of chemokines in MM could aid in identifying potential biomarkers and developing new therapeutic strategies and targets. Purpose To summarize the complicated role of chemokines in MM, discuss their potential as biomarkers, and introduce several treatments based on chemokines. Methods Pubmed, Web of Science, ICTRP, and Clinical Trials were searched for articles and research related to chemokines. Publications published within the last 5 years are selected. Results Malignant cells can utilize chemokines, including CCL2, CCL3, CCL5, CXCL7, CXCL8, CXCL12, and CXCL13 to evade apoptosis triggered by immune cells or medication, escape from bone marrow and escalate bone lesions. Other chemokines, including CXCL4, CCL19, and CXCL10, may aid in recruiting immune cells, increasing their cytotoxicity against cancer cells, and inducing apoptosis of malignant cells. Conclusion Utilizing anti-tumor chemokines or blocking pro-tumor chemokines may provide new therapeutic strategies for managing MM. Inspired by developed CXCR4 antagonists, including plerixafor, ulocuplumab, and motixafortide, more small molecular antagonists or antibodies for pro-tumor chemokine ligands and their receptors can be developed and used in clinical practice. Along with inhibiting pro-tumor chemokines, studies suggest combining chemokines with chimeric antigen receptor (CAR)-T therapy is promising and efficient.

show abstract

Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer

Cited by 14 publications

References 168 publications

Macrophage Inflammatory Proteins (MIPs) Contribute to Malignant Potential of Colorectal Polyps and Modulate Likelihood of Cancerization Associated with Standard Risk Factors

Macrophage Inflammatory Proteins (MIPs) Contribute to Malignant Potential of Colorectal Polyps and Modulate Likelihood of Cancerization Associated with Standard Risk Factors

JAK1 Is a Novel Target of Tumor- and Invasion-Suppressive microRNA 494-5p in Colorectal Cancer

Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)

Contact Info

Product

Resources

About